Health and Healthcare

Health and Healthcare Articles

All Health and Healthcare Articles

5864 Articles

Douglas A. McIntyre | Dec 7, 2006 at 3:06 PM EST

Stent Safety Issues at the FDA….Hogwash

Stock Tickers: BSX, JNJ, ANPI, SRDX, CONR, BMY, SNY, ABT, MDT The FDA review of stents should not change the…

Douglas A. McIntyre | Dec 7, 2006 at 10:14 AM EST

Boston Scientific Goes To The Mattresses

Stocks: (MRK)(BSX)(JNJ)(PFE) Yet another investigation of the health affect of stents. Where will it end? The FDA is bringing in…

Douglas A. McIntyre | Dec 7, 2006 at 3:57 AM EST

Halozyme Signs Deal with Roche, Continues to Impress

From BioHealth Investor I recommended Halozyme Therapeutics (HTI) in August (and mentioned it again last week that I was holding…

Douglas A. McIntyre | Dec 6, 2006 at 12:56 PM EST

Let’s Hope They Told Pfizer (PFE)

Comscore has released data that say that 33 million people researched presciption medications on the internet in Q3. That is…

Douglas A. McIntyre | Dec 6, 2006 at 12:56 PM EST

Let’s Hope They Told Pfizer (PFE)

Comscore has released data that say that 33 million people researched presciption medications on the internet in Q3. That is…

Douglas A. McIntyre | Dec 6, 2006 at 8:45 AM EST

Merck Putting Vioxx Behind It (MRK)(PFE)

Vioxx lawsuit could drag on for years, even a decade. But, Merck is looking ahead. It confirmed 2006 guidance and…

Douglas A. McIntyre | Dec 6, 2006 at 4:31 AM EST

Biotech Landmark Study Finds Challenges to Industry

From BioHealth Investor BayBio, Northern California’a leading biotechnology industry organization, published its landmark study BayBio: IMPATCT 2007. What does Northern…

Douglas A. McIntyre | Dec 6, 2006 at 4:27 AM EST

Searching for Values in the Drug Stock Universe

By Chad Brand of Peridot Capitalist Not too long ago I wrote about pharmaceutical giant Pfizer (PFE) and how it…

Douglas A. McIntyre | Dec 5, 2006 at 6:11 PM EST

Cramer Has a Stent Trade

On tonight’s MAD MONEY show on CNBC, Cramer reviewed what the state of the stent market will be. There is…

Douglas A. McIntyre | Dec 5, 2006 at 8:50 AM EST

Gambling Drug Fails Trials; Somaxon Shares Lower

Somaxon Pharmaceuticals (SOMX-NASDAQ) has announced essentially failed results from the company’s Phase 2/3 clinical trial evaluating 20 mg and 40…

Douglas A. McIntyre | Dec 5, 2006 at 4:24 AM EST

Pfizer Setback Disappointing, Not Catastrophic

By Chad Brand of Peridot Capitalist I was actually planning a broader pharmaceutical post , but in light of the…

Douglas A. McIntyre | Dec 5, 2006 at 4:15 AM EST

Onyx Pharma Tumbles As Skin Cancer Drug Fails Phase III

From BioHealth Investor Shares of Onyx Pharmaceuticals (ONXX) dropped more than 30% on Monday after the company announced at a…

Douglas A. McIntyre | Dec 4, 2006 at 2:42 PM EST

What Elese Is Wrong With Pfizer

Pfizer (PFE) had its CEO interviwed by Mike Huckman on CNBC today. Mike Huckman even asked him how a "guy…

Douglas A. McIntyre | Dec 4, 2006 at 9:19 AM EST

Cramer Comments on Pfizer; Also What to Expect on PFE From Here

This morning Cramer on TheStreet.com posted his comments regarding Pfizer’s (PFE) drug blow-up this weekend. You’ll need to go visit…

Douglas A. McIntyre | Dec 3, 2006 at 7:15 AM EST

Pfizer Death Drug (PFE)

Those who read this column regularly know our doubts about Prizer’s new blockbuster drugs. These are the ones the are…

1 … 389 390 391 392

Health and Healthcare Articles

All Health and Healthcare Articles

Stent Safety Issues at the FDA….Hogwash

Boston Scientific Goes To The Mattresses

Halozyme Signs Deal with Roche, Continues to Impress

Let’s Hope They Told Pfizer (PFE)

Let’s Hope They Told Pfizer (PFE)

Merck Putting Vioxx Behind It (MRK)(PFE)

Biotech Landmark Study Finds Challenges to Industry

Searching for Values in the Drug Stock Universe

Cramer Has a Stent Trade

Gambling Drug Fails Trials; Somaxon Shares Lower

Pfizer Setback Disappointing, Not Catastrophic

Onyx Pharma Tumbles As Skin Cancer Drug Fails Phase III

What Elese Is Wrong With Pfizer

Cramer Comments on Pfizer; Also What to Expect on PFE From Here

Pfizer Death Drug (PFE)

XRP Price Prediction: 3 AI Models Predict Where XRP Will Trade by December 2026

QDVO’s 32% Return Masks a Hidden Risk for Income Investors

Half of America Still Feels Financially Exposed Despite 8% Jump in Security

Half of America Still Feels Financially Exposed Despite 8% Jump in Security

52% of Americans Are Building Wealth While Ignoring Their Greatest Risk

Kevin Warsh Would Be a Hawk at the Fed, but Productivity Boom Could Prevail

Ray Dalio: ‘We’re On the Brink’ of Major Problems Within 2 Years

Health and Healthcare Articles

All Health and Healthcare Articles

Stent Safety Issues at the FDA….Hogwash

Boston Scientific Goes To The Mattresses

Halozyme Signs Deal with Roche, Continues to Impress

Let’s Hope They Told Pfizer (PFE)

Let’s Hope They Told Pfizer (PFE)

Merck Putting Vioxx Behind It (MRK)(PFE)

Biotech Landmark Study Finds Challenges to Industry

Searching for Values in the Drug Stock Universe

Cramer Has a Stent Trade

Gambling Drug Fails Trials; Somaxon Shares Lower

Pfizer Setback Disappointing, Not Catastrophic

Onyx Pharma Tumbles As Skin Cancer Drug Fails Phase III

What Elese Is Wrong With Pfizer

Cramer Comments on Pfizer; Also What to Expect on PFE From Here

Pfizer Death Drug (PFE)

XRP Price Prediction: 3 AI Models Predict Where XRP Will Trade by December 2026

QDVO’s 32% Return Masks a Hidden Risk for Income Investors

Half of America Still Feels Financially Exposed Despite 8% Jump in Security

Featured Reads

Half of America Still Feels Financially Exposed Despite 8% Jump in Security

52% of Americans Are Building Wealth While Ignoring Their Greatest Risk